HBW 1020
Alternative Names: HBW-1020Latest Information Update: 30 Aug 2021
Price :
$50 *
At a glance
- Originator Chengdu Hyperway Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors; Tropomyosin-related kinase agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Aug 2021 Preclinical trials in Cancer in China (unspecified route) (Chengdu Hyperway Pharmaceuticals pipeline, August 2021)